The Pharmacist Who Didn’t Know He Was Dying
52-Year-Old Male · Mixed Hyperlipidemia · Pre-Diabetes
Calcium score zero is not a green light. It is only a test for calcified plaque, and the most dangerous plaque is soft, non-calcified, and completely invisible to calcium scoring.
What Did Traditional Medicine Say?
Traditional Cardiology
- CAC score of 0 (4 months prior) → 'reassuring, no significant disease'
- Treadmill stress test: 11 min, no EKG changes → NORMAL
- Echocardiogram: normal function, no valvular disease → NORMAL
- Standard lipid panel: LDL 127, total cholesterol 199 → 'managed'
- No further imaging ordered — follow up 'as needed'
Pulse Perfect Approach
- CAC of 0 means zero calcified plaque — it cannot see soft (non-calcified) plaque at all
- Coronary CTA + Heartflow Analysis revealed <90% LAD stenosis from 100% non-calcified plaque
- FFRCT (HeartFlow) confirmed hemodynamic significance: FFR 0.79 in mid LAD
- NMR LipoProfile: LDL-P 1,534 nmol/L, Pattern B, far more atherogenic than LDL alone
- Patient underwent cardiac catheterization and stenting — a life was saved
Coronary CTA with HeartFlow Analysis + FFRCT
| Vessel | Finding | % Stenosis | FFRCT Value | Clinical Decision |
|---|---|---|---|---|
| Left Main | Non-calcified plaque, 23 mm³ | < 10% | N/A | Medical Management |
| Proximal LAD | 100% non-calcified plaque, 807 mm³ | < 90% | 0.79 (mid) / 0.76 (distal) | ⚠️ Hemodynamically significant |
| Proximal RCA | Non-calcified plaque | 100% | N/A | ⚠️ Hemodynamically significant |
| Mid LCx | Non-calcified plaque | 25% | N/A | Medical Management |
FFRCT Interpretation: A value below 0.80 indicates hemodynamically significant stenosis, meaning the narrowing is actively restricting blood flow to the heart muscle. This patient’s LAD readings of 0.79 and 0.76 confirmed significant ischemia. He proceeded to cardiac catheterization and coronary stenting. Without this evaluation, he would have had a heart attack.
Advanced Lipid
| Marker | Result | Significance |
|---|---|---|
| LDL Particle Number (LDL-P) | 1,534 nmol/L | High — elevated atherogenic particle burden |
| LDL Pattern | Pattern B (small dense) | Most atherogenic LDL type — invisible to standard LDL test |
| Lp(a) | 216.2 nmol/L | Severely elevated — major independent genetic risk factor |
| ApoB | 95 mg/dL | Elevated — goal < 60 in confirmed ASCVD |
| hs-CRP | 1.5 mg/L | Elevated — active vascular inflammation |
| EPA/DHA ratio | Abnormal | Omega-3 deficiency — pro-inflammatory state |
Diagnostic imaging and lab testing can often be coordinated through existing insurance. HSA and FSA funds may apply to membership fees — confirm with your plan administrator.
Key Clinical Teaching Point
Diagnostic imaging and lab testing can often be coordinated through existing insurance. HSA and FSA funds may apply to membership fees — confirm with your plan administrator.
- A pharmacist — someone who dispenses cardiac medications daily, was unknowingly on the verge of a heart attack. Standard tests gave him (and his physicians) false reassurance
- Stress test, echocardiogram, and CAC all returned normal. Only the Coronary CTA with Heartflow plaque analysis and FFRCT revealed the true picture.
- Elevated LDL particle number with Pattern B (small dense LDL) is far more atherogenic than standard LDL cholesterol suggests. These particles are small enough to penetrate and lodge in arterial walls.
- Lp(a) of 216.2 nmol/L is a major, largely genetic risk factor that is never captured on a standard lipid panel. It dramatically increases cardiovascular risk and requires specific testing to identify.
- FFRCT allows non-invasive physiologic assessment of stenosis significance, guiding the decision to proceed to catheterization without the risk and cost of diagnostic invasive testing.